Medical Device Sourcing for Central Asia: A Market Entry Guide to Uzbekistan and Kazakhstan

Medical device sourcing for Central Asia represents one of the fastest-growing opportunities for European suppliers that remains underrecognised. Uzbekistan’s medical device market reached USD 1.8 billion in 2025, growing 21 percent year-on-year according to the State Pharmacy Committee. Local manufacturers cover only 18 percent of market demand, meaning over 80 percent of the market is import-dependent.

Kazakhstan’s medical device market also reached USD 688.3 million in 2024, and is projected to grow at a compound annual growth rate (CAGR) of 5.44 percent, reaching USD 850.9 million by 2028. Cardiology devices form the largest segment of this market.

Lenus Health exports medical devices from Germany to Central Asian markets, including Uzbekistan and Kazakhstan. All our products carry CE marking and comply with the EU Medical Device Regulation (MDR), and we are familiar with the differing registration requirements of each country in this region.

In this article we explain how the Central Asia medical device market is growing, what regulatory requirements apply to entering this market, and how to select the right European supplier for this region.

For international supply and commercial inquiries regarding this type of product, please contact the Lenus Health sales team.

Table of Contents

1. Why the Central Asia Medical Device Market Matters
2. Key Drivers of Market Growth
3. Differing Regulatory Requirements by Country
4. Supply Chain and Logistics Challenges
5. Trade Routes and Regional Distribution Hubs
6. The Role of Lenus Health in Supplying Medical Devices to Central Asia
7. How to Select the Right European Supplier
8. Conclusion
9. Frequently Asked Questions

1. Why the Central Asia Medical Device Market Matters

Central Asia, particularly Uzbekistan and Kazakhstan, is experiencing one of the fastest medical device market growth rates globally. Uzbekistan’s population exceeds 37 million people, with 3 million living in its vibrant capital, Tashkent. Kazakhstan’s healthcare spending rose from 3.2 percent of GDP in 2020 to an estimated 4.1 percent in 2025.

This structural growth, combined with only 18 percent local manufacturing coverage in Uzbekistan, means a genuine opportunity exists for European suppliers who can meet this rising demand with stable quality.

2. Key Drivers of Market Growth

• Digitisation and government localisation programmes: Uzbekistan’s pharmaceutical and medical device market has been expanding at 15 to 20 percent annually, driven by government digitisation and localisation programmes.
• Removal of customs clearance fees: Since January 1, 2025, the customs clearance fee for medical devices has been abolished in Uzbekistan, making imports cheaper and more streamlined.
• Kazakhstan’s growing technology infrastructure: Kazakhstan’s technology park, Astana Hub, has attracted over 1,700 participants and is fostering advanced manufacturing certification, including cleanroom capabilities.
• Rising chronic disease burden: Increasing diabetes diagnoses and chronic disease prevalence have raised demand for specialised diagnostic and treatment devices across the region.

Together, these factors indicate that Central Asia’s market growth is structurally rooted and expected to continue in the coming years.

3. Differing Regulatory Requirements by Country

One of the most complex aspects of entering the Central Asia market is regulatory fragmentation across countries. Kazakhstan follows its own medical device classification, Uzbekistan defers to a mix of Russian GOST and ISO standards, while Kyrgyzstan has an accelerated simplified pathway. This fragmentation creates compliance complexity and limits large-scale procurement.

• Uzbekistan: Medical device registration is handled through the State Pharmacy Committee. Under Cabinet of Ministers Resolution No. 738, approved in November 2025 and effective from February 2026, the registration process has been reformed. Each device is listed separately in the state services catalogue and assigned its own tariff, expressed in Basic Calculated Values (BCV), equal to 412,000 UZS or USD 33 as of 2026.
• Kazakhstan: As the region’s logistics gateway, Kazakhstan is a member of the Eurasian Economic Union (EAEU), which includes Kazakhstan, Kyrgyzstan, and Russia. This union applies reduced or zero duty rates for certified medical components, lowering the effective import cost for buyers in member states.
• Uzbekistan and Tajikistan outside the EAEU: These countries apply separate import duty regimes that must be factored into cost planning.

A precise understanding of these differences is essential for any supplier seeking a sustainable presence across the region.

4. Supply Chain and Logistics Challenges

Central Asia is structurally an importer, not a producer. Exports from the region are negligible, and most trade flows are unilateral, from manufacturing centres in Europe and Asia to end users in the region.

Supply bottlenecks arise from incomplete supplier qualification documentation for new manufacturers, customs delays of one to three weeks, and cold-chain requirements for certain pre-sterilised assemblies. Lead times of 10 to 18 weeks from order to delivery are typical.

To mitigate risk, larger distributors maintain 12 to 20 weeks of safety stock, particularly for high-volume lines such as insulin needles. Regulatory registration for new component suppliers can stretch 6 to 18 months in Kazakhstan and Uzbekistan, creating barriers for new entrants and prolonging dependence on a narrow base of approved vendors.

5. Trade Routes and Regional Distribution Hubs

Kazakhstan serves as the regional logistics gateway, with major importers holding bonded warehouses in Almaty. Uzbekistan is the second-largest point of entry and is growing faster due to demographic weight and healthcare modernisation.

Regional distribution hubs in Almaty, Kazakhstan and Tashkent, Uzbekistan consolidate inventory and service smaller markets, reducing lead times for downstream clinics. Within the region, minor cross-border trade occurs: Kazakhstan re-exports small volumes to Kyrgyzstan and Tajikistan, leveraging its superior logistics infrastructure.

Uzbekistan’s primary import partners for medicinal products are Russia, China, India, South Korea, and Germany, indicating Germany remains one of this market’s trusted sources.

6. The Role of Lenus Health in Supplying Medical Devices to Central Asia

Lenus Health exports medical devices from Germany to Central Asian markets, including Uzbekistan and Kazakhstan. Our portfolio includes medical disposables, cardiovascular surgery devices, and orthopedic and prosthetic products.

We are familiar with each country’s differing registration requirements, from Uzbekistan’s Resolution No. 738 to Kazakhstan’s independent classification, and provide a complete documentation package with every shipment, including CE certification, Declaration of Conformity, and translated documents where required. Our team understands that delivery timelines in this region can be lengthy and provides advance planning to manage this challenge.

If your organisation in Central Asia needs a reliable supplier of medical devices from Europe, the Lenus Health team is ready to review your exact market requirements and propose the right sourcing solution.

7. How to Select the Right European Supplier

Selecting the right supplier for the Central Asia market requires attention to several region-specific factors.

• Familiarity with each country’s registration requirements: The supplier should be familiar with the region’s regulatory fragmentation.
• Managing longer delivery timelines: The ability to plan in advance for 10 to 18 week delivery timelines is essential.
• Safety stock capacity: For high-volume products, the supplier should maintain adequate inventory capacity.
• Understanding of duty regime differences: Familiarity with the difference between EAEU member and non-member countries matters.
• Track record of successful exports to the region: The supplier’s prior experience in this region is a meaningful operational advantage.

A reputable supplier should be able to provide a sample of successful documentation registered in your target market and offer realistic timelines from the initial enquiry.

Conclusion

The Central Asia medical device market is entering a period of rapid growth, with Uzbekistan growing at 21 percent annually and Kazakhstan growing steadily at 5.44 percent. This growth stems from rising government healthcare spending, digitisation programmes, and limited local manufacturing coverage that keeps the region heavily import-dependent.

For importers and distributors in this region, this means the need for a European supplier who understands each country’s regulatory fragmentation and can manage the region’s longer delivery timelines through advance planning is steadily increasing. Germany remains one of this market’s trusted trading sources.

Lenus Health, with operational experience in Central Asian markets, familiarity with each country’s differing regulatory requirements, and complete CE and MDR documentation for every shipment, is a partner that manages this complexity. If your organisation needs a reliable supplier of medical devices for Central Asia from Europe, the Lenus Health team is ready to listen to your specific requirements.

For international supply and commercial inquiries regarding this type of product, please contact the Lenus Health sales team.

Frequently Asked Questions

• How fast is the Central Asia medical device market growing?
  Uzbekistan’s market grew 21 percent year-on-year, reaching USD 1.8 billion in 2025. Kazakhstan’s market is projected to grow at a 5.44 percent annual growth rate, from USD 688.3 million in 2024 to USD 850.9 million by 2028.
• Why are regulatory requirements complex in Central Asia?
  Each country has a different framework. Kazakhstan follows its own classification, Uzbekistan defers to GOST and ISO standards, and Kyrgyzstan has a simplified pathway, creating regulatory fragmentation.
• What is the typical delivery timeline for medical devices to Central Asia?
  Typical lead times from order to delivery are 10 to 18 weeks. Regulatory registration for new suppliers can take 6 to 18 months.
• Which countries are members of the Eurasian Economic Union (EAEU)?
  Kazakhstan, Kyrgyzstan, and Russia are EAEU members, which applies reduced duty rates for certified medical components. Uzbekistan and Tajikistan are outside this union.
• Why is Germany an important trade source for Uzbekistan?
  Germany is one of Uzbekistan’s top five import partners for medicinal products, alongside Russia, China, India, and South Korea, reflecting long-standing trust in German product quality.